Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | PI4KA | P42356 | 1/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2619226 | 0.78 | RET (0.61) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL11363 | 0.76 | XDH (1.00) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL30763272 | 0.76 | XDH (0.63) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL29351045 | 0.76 | XDH (1.00) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL28839743 | 0.76 | XDH (0.63) | XDHRETPI4KALRRK2PI4K2B | |
| Hydrochloric Acid SCHEMBL1741653 | 0.74 | XDH (0.96) | XDHRETPI4KALRRK2PI4K2B | |
| Tisopurine SCHEMBL93974 | 0.74 | XDH (0.61) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL15504523 | 0.74 | XDH (0.61) | XDHRETPI4KALRRK2PI4K2B | |
| Hydrochloric Acid SCHEMBL14742346 | 0.74 | XDH (0.96) | XDHRETPI4KALRRK2PI4K2B | |
| Allopurinol SCHEMBL4627 | 0.74 | XDH (0.61) | XDHRETPI4KALRRK2PI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 735 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115650986-B | Cinnamoyl amino pyrazolo [3,4-d ] pyrimidine compound, and preparation and application thereof | 浙江工业大学 | 2024-07-30 | — | — | CN | claimed |
| CN-115557953-B | N-phenylbenzoylamino pyrazolopyrimidine compound, and preparation and application thereof | 浙江工业大学 | 2024-07-19 | — | — | CN | claimed |
| CN-117586267-A | Preparation method of 4-bromopyrazole [3,4-D ] -pyrimidine | 山东百启生物医药有限公司 | 2024-02-23 | — | — | CN | claimed |
| CN-115650986-A | Cinnamyl amino pyrazolo [3,4-d ] pyrimidine compound and preparation and application thereof | 浙江工业大学 | 2023-01-31 | — | — | CN | claimed |
| CN-115557953-A | N-phenyl benzoyl amino pyrazolopyrimidine compound and preparation and application thereof | 浙江工业大学 | 2023-01-03 | — | — | CN | claimed |
| CN-111848419-B | (E) Synthesis method of (E) -4-hydroxy-3-methyl-2-butenylamine and zeatin | 郑州猫眼农业科技有限公司 | 2021-11-23 | — | — | CN | claimed |
| CN-111848419-A | (E) Synthesis method of (E) -4-hydroxy-3-methyl-2-butenylamine and zeatin | 郑州猫眼农业科技有限公司 | 2020-10-30 | — | — | CN | claimed |
| CN-111606909-A | Pyrazolopyrimidine compound, pharmaceutical composition thereof, preparation method and application | 浙江大学 | 2020-09-01 | — | — | CN | claimed |
| US-8349847-B2 | Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents | KONAKANCHI DURGA PRASAD (IN) | 2013-01-08 | — | — | US | claimed |
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2010-11-25 | — | — | US | claimed |
| EP-2247596-A2 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS | Natco Pharma Limited (IN) | 2010-11-10 | — | — | EP | claimed |
| WO-2009098715-A2 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2009-08-13 | — | — | WO | claimed |
| EP-1628979-A1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-01 | — | — | EP | claimed |
| WO-2004101568-A1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | claimed |
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| CN-117586267-B | Preparation method of 4-bromopyrazole [3,4-D ] -pyrimidine | 山东百启生物医药有限公司 | 2026-05-01 | — | — | CN | disclosed |
| EP-4704829-A2 | SUBSTITUTED BICYCLIC HETEROCYCLE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-0042593-A1 | Aryloxy-propanol amines, process for their preparation and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1981-12-30 | — | — | EP | disclosed |
| US-4087423-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1978-05-02 | — | — | US | disclosed |
| US-4053474-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | DPYD, TYMP, TYMS | XDH 143/4885RET 1971/4885PI4KA 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.